Curis, Inc. Share Price Nasdaq
Equities
US2312691015
Biotechnology & Medical Research
Sales 2024 * | 8.78M 689M | Sales 2025 * | 8.8M 690M | Capitalization | 65.84M 5.16B |
---|---|---|---|---|---|
Net income 2024 * | -48M -3.77B | Net income 2025 * | -53M -4.16B | EV / Sales 2024 * | 7.5 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.49 x |
P/E ratio 2024 * |
-1.81
x | P/E ratio 2025 * |
-2.43
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
Latest transcript on Curis, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 28/03/16 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 25/07/22 |
Chief Tech/Sci/R&D Officer | - | 02/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 31/10/03 |
Martyn Greenacre
CHM | Chairman | 82 | 13/02/00 |
James Dentzer
CEO | Chief Executive Officer | 57 | 28/03/16 |
1st Jan change | Capi. | |
---|---|---|
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |